# This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

Source: https://onco.cc/trials/nct07878988/  
OnCo record `nct07878988` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of LTZ-232 run by LTZ Therapeutics, Inc., now recruiting.

## Summary

This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors is a phase 1 interventional study registered as NCT07878988 by LTZ Therapeutics, Inc., with 152 participants planned, started 2026-10-28. Conditions recorded: Colorectal Cancer, Advanced/Metastatic Solid Tumor, Solid Tumor (Phase I), EPCAM and Colon Cancer. Interventions recorded: LTZ-232.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07878988
- Phase: 1
- Setting: A Phase 1/1b, Muticenter Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors
- Sponsor: LTZ Therapeutics, Inc.
- Enrolled: 152

## Sources

- ClinicalTrials.gov NCT07878988: https://clinicaltrials.gov/study/NCT07878988

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [LTZ-232](https://onco.cc/drugs/ltz-232/)
- companies: [LTZ Therapeutics](https://onco.cc/companies/ltz-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07878988.json